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ABSTRACT  
The chemotherapeutic Parthenolide is an exciting new candidate for the treatment of acute 
lymphoblastic leukaemia but like many other small molecule drugs, has low aqueous solubility. As a 
consequence, Parthenolide can only be administered clinically in the presence of harmful co-solvents. 
Accordingly, we describe the synthesis, characterisation and testing of a range of biocompatible 
triblock copolymer micelles as particle-based delivery vectors for the hydrophobic drug Parthenolide. 
The drug-loaded particles are produced via an emulsion-to-micelle transition method and the effects of 
introducing anionic and cationic surface charges on stability, drug sequestration, biocompatibility and 
efficacy are investigated. Significantly, we demonstrate high levels of efficacy in the organic solvent 
free systems against human mesenchymal stem cells and primary T-acute lymphoblastic leukaemia 
patient cells, highlighting the effectiveness of the delivery vectors for the treatment of acute 
lymphoblastic leukaemia. 
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INTRODUCTION  
Many therapeutics exhibit high efficacy but suffer from low aqueous solubility, which limits their 
application as effective treatments.1 Numerous strategies exist in order to improve the formulation and 
subsequent administration of such compounds, including the incorporation of organic co-solvents, 
production of synthetic analogues with greater hydrophilicity or use of prodrug precursors2. 
Unfortunately, the addition of organic co-solvents often results in adverse cytotoxic effects, severely 
limiting their clinical use. Furthermore, chemical modifications to introduce greater hydrophilicity not 
only require additional synthetic steps, but can also reduce drug efficacy. As a consequence, the 
application of polymer based micelles, vesicles and nanoparticles as drug delivery vectors is increasing 
substantially.3 The attractiveness of polymer-based systems begins with their high degree of inherent 
tunability, for example, polymeric systems can be designed to respond to external stimuli such as 
temperature, pH or light allowing a controlled release profile.4-6 Moreover, the incorporation of specific 
functional groups on the vector provides a robust route to biomolecule conjugation7 or surface charged 
modifications to generate neutral, anionic, cationic or zwitterionic species, which can both aid in the 
targeting of specific cell populations to limit systemic exposure.8-11 
 
Acute lymphoblastic leukaemia (ALL) is a disease with an incidence of 1 - 4.75 per 100,000 people 
globally12, but with a much higher incidence in children, peaking at between 2 and 5 years of age.13-15 
With current treatment protocols, around 90% of childhood ALL achieve clinical remission.16-18 
However, approximately 20% of children relapse due to the persistence and continued proliferation of 
leukaemia cells that are resistant to therapy and many cases who relapse do not survive.19 Treatment 
itself is extremely toxic and can be life threatening.20 The lack of an effective, less toxic treatment 
programme has driven the requirement for alternative chemotherapeutic treatments and delivery 
mechanisms with several candidates as attractive targets including the drug Parthenolide (PTL).1,21 PTL 
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(Figure 1A) is a natural product (sesquiterpene lactone) derived from Tanacetum parthenium (also 
known as feverfew) that has been shown to have excellent chemotherapeutic potential in the treatment 
of AML, and more recently ALL, but has an inherently poor aqueous solubility limiting 
bioavailability.19,22,23 Though several studies investigating the use of a PTL (dimethylamino) analogue 
with improved aqueous solubility have been reported, its effectiveness as anti-proliferative agents is 
less pronounced and requires additional synthetic steps. A number of other analogues have also been 
recently reported, but also have reduced efficacy and at present are not suitable alternatives.24,25  
 
Pluronics (also known as poloxamers) are a class of triblock copolymers of poly(ethylene) glycol 
(PEG) and poly(propylene) glycol (PPG) in the configuration PEG-PPG-PEG, and their complex 
mesophase behaviour makes them excellent candidates as drug delivery vectors.26 For example, 
variations in the PEG (hydrophilic) and PPG (hydrophobic) compositions elicit notable differences in 
their critical micelle concentration (CMC) and critical micelle temperature (CMT).27-29 This versatility 
has led to the application of Pluronic nanocarriers as vectors for drug delivery, as the hydrophobic PPG 
core provides an environment for compounds with poor aqueous solubility to be sequestered.29,30 
Notable examples include the use of folic acid functionalised P123/F127 mixed nanocarriers for 
paclitaxel delivery in multidrug resistant tumours and thermally responsive F127-chitosan nanocarriers 
for the intracellular delivery of small molecules.31-33 Significantly, cationic F127-PEI conjugates have 
been shown to improve both the delivery of the anti-cancer compound docetaxel and a plasmid 
encoding the serine protease inhibitor TFPI-2.34 These examples highlight the adaptability of Pluronic 
nanocarrier systems functionalised with small molecules, proteins or polymers as drug or gene delivery 
vectors.  
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Figure 1: A. The structure of the chemotherapeutic parthenolide. B. Triblock co-polymer structure of 
Pluronic F127.  C. Scheme highlighting the synthetic strategy to parthenolide loaded micelle formation. 
i. Monomeric F127 ii. F127 Micelle formation above CMT or CMC. iii. Addition of CHCl3 and PTL 
forming a stable emulsion by vortexing. iv. Rotary evaporation to remove CHCl3 and encapsulate PTL 
in solvent-free micelles. D. Micelle systems i. Neutral ii. Anionic (oxidised) iii. Cationic (PEI-
conjugated). 
In this study, we have produced a range of Pluronic micellar structures as vectors for the solvent free 
delivery of PTL for the treatment of ALL. Significantly, we demonstrate that PTL loaded F127 
micelles could be used as an alternative for co-solvent PTL delivery to primary T-ALL cells. 
Furthermore, drug efficacy was varied between micelles displaying cationic charges compared to 
anionic formulations, emphasizing how charge can influence membrane interactions and subsequent 
drug delivery. 
1 10
0
5
10
15
20
25
30
35
Hydrodynamic Diameter (nm)
In
te
ns
ity
 (%
)
		
	
		
	
		
	
		
	
		
	
		
	
D i ii iii 
Neutral Anionic Cationic
10% Oxidised  
species
10% PEI-conjugated 
 species
Parthenolide
Hydrophobic
Hydrophilic
A B 
C 
		
	
		
	
	 		
Hydrophilic
Hydrophobic
>CMT or >CMC Rotary Evaporator
- CHCl3 
		
	
		
		
		
	
	 	
	
		 	
+PTL
(CHCl3)
PTL 
Nanocarrier
15-20 d.nm 15-20 d.nm
5-20 d.µm4-5 d.nm
	 	
	 	
	
	 	
		 	
	
	
i 
ii 
iii 
iv 
 6 
EXPERIMENTAL 
Reagents 
Parthenolide was purchased from Santa Cruz Biotechnology Inc. (Heidelberg, Germany) and of the 
highest available purity. All other reagents unless otherwise specified were purchased from either 
Sigma Aldrich Company Ltd (Poole, UK) or Life Technologies Ltd (Paisley, UK) and used without 
further modification. 
 
Donor cells 
Bone marrow samples were obtained with consent from healthy donors from whom mesenchymal 
stem cells were isolated in full accordance with Bristol Southmead Hospital Research Ethics 
Committee guidelines (reference #078/01). Bone marrow derived diagnostic primary T-ALL samples 
were collected, with consent, approved by University Hospitals Bristol Trust, Bristol, UK (REC 
12/LO/1193). Primary T-ALL cells were isolated via ficoll mediated density gradient centrifugation 
and cryopreserved in vapour phase N2 prior to use. 
 
PTL loaded micelle synthesis 
Parthenolide loaded micelles were synthesised using a modified strategy devised by Collins et al as 
PTL in an aqueous 10 wt % F127 solution alone does not enable effective partitioning into the micelles 
even with significant agitation.30 In brief 12 mg of Parthenolide dissolved in 1 mL of chloroform is 
added to a 20mL aqueous 10 wt % Pluronic solution (all variations) at room temperature. The mixture 
is vortexed vigorously to ensure a stable homogeneous emulsion and partition of Parthenolide into the 
organic (chloroform) phase. The mixture is placed on a rotary evaporator (BUCHI UK Ltd, 
Manchester, UK) at 42 °C and 150 mbar for 60 minutes causing evaporation and elimination of 
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chloroform leaving (2.4 mM / 0.6 mgml-1) Parthenolide loaded Pluronic micelles free from organic 
solvents for further use. 
 
DPH assay (CMC and CMT) 
1,6-diphenyl-1,3,5-hexatriene (DPH) displays a dramatic shift in fluorescence intensity when in a 
hydrophobic environment and is therefore an excellent probe for micelle formation. CMC can therefore 
be defined as follows: 200 μL of Pluronic (0 wt% - 5 wt%) is aliquoted in triplicate in a 96-well plate 
to which 10 μL DPH (saturated) in MeOH is added. Samples were placed on a rotator at 120 rpm for 
10 minutes to ensure a homogenous suspension prior to measuring fluorescence (excitation 355 nm, 
emission 488 nm) using a Mithras LB 940 plate reader (Berthold Technologies GmbH & Co. KG, Bad 
Wildbad, Germany) with dramatic increases in fluorescence indicative of micelle formation. CMT was 
measured using a temperature controlled (Quantum Northwest Inc, Washington, USA) UV-Vis 
Spectrophotometer (Agilent Technologies LDA UK Limited, Stockport, UK). 400 μL of 2 wt% 
Pluronic plus 20 μL DPH (saturated) in MeOH was mixed and transferred to a quartz cuvette (1 cm 
pathlength) and absorbance measured continuously at 360nm from 6 °C to 40 °C at 1°C/min with a 
rapid increase in absorbance indicative of the onset of micelle formation. 
 
Dynamic light scattering, Static light scattering and Zeta Potentiometry 
All dynamic light scattering (DLS), static light scattering (SLS) and zeta potential measurements 
were performed using a Malvern Nano ZSP zetasizer (Malvern Instruments Ltd, UK) with samples 
filtered (0.22 μm) to remove large aggregates and contaminants immediately prior to analysis. 
Monomer size (DLS) and MW (SLS) were defined at a concentration and temperature (4 or 25 °C) 
combination below the CMC and CMT. Micelle size (DLS) and MW (SLS) were defined at a 
concentration and temperature (37 or 50 °C) combination above the CMC and CMT with minimum 
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equilibration time of 10 minutes. CMT measurements were performed at 1°C intervals at a 
concentration of 1 wt % (10 minute equilibration) from 4 – 40 °C with the onset of well-defined 
micelles indicative of the CMT. When highlighting the retention of PTL with respect to thermal 
reversibility temperatures of 4 and 42 °C were used with 10 wt% F127 micelles loaded with 0.6 
mg.mL-1 PTL. Each of the reported values were performed in pure H2O solutions. 
 
Small Angle X-ray Scattering 
Small Angle X-ray Scattering (SAXS) was measured using a GANESHA SAXS instrument 
(SAXSLAB, Denmark). The X-ray wavelength was 1.5 Å (copper Kα radiation), and scattering was 
detected using a Pilatus 300K 20Hz detector (Dectris AG Switzerland) giving a q-range of 0.01 – 0.3 
Å-1 with measurements performed under vacuum. Samples were prepared to a final concentration of 2 
wt% F127 ± 0.12 mg mL-1 (483 μM) PTL (a 5-fold dilution from the prepared stock in order to avoid 
the onset of a strong structure factor contribution from particle-particle interactions) in deionised water 
and sealed in quartz capillaries (SAXSLAB, Switzerland). Temperature was controlled using a Julabo 
temperature controller (Julabo GmbH, Germany) with a thermocouple within the sample chamber 
ensuring that an accurate and constant temperature was attained. Water and empty cell backgrounds 
were subtracted from the sample measurements. The radius of gyration and I(0) were obtained from the 
reciprocal and real space data using GNOM. Form factor fitting was performed in IGOR using a model 
form factor describing a population of spheres with uniform scattering length density 
(PolyRectSpheres, NCNR SANS analysis macro). A spherical model was chosen rather than a core 
shell model as the difference in contrast between phases was not sufficient to be distinguished using a 
benchtop instrument. The scale parameter, corresponding to the volume fraction of F127, was fixed at 
0.018, the background parameter was then fitted and subsequently fixed. Polydispersity and solvent 
scattering length density (SLD) were held at 0.01 and 9.43E-6 Å-2 respectively. The data were then 
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fitted, floating the radius and sphere SLD parameters. The micelle aggregation number was calculated 
by first determining f, the ratio of F127 to water in the micelle (Equation 1).  
 
Equation 1.   𝑓 = #(%)'()*+,,+-./()*+,,+.(01234567012859)5 
 
Where f is the volume fraction of F127 in the micelle, φmicelles is the volume fraction of micelles in the 
sample, Vmicelle is the micelle volume, calculated from the form factor fit radius, and I(0) is the 
extrapolated scattering intensity at zero-angle, determined from the real space transformation of the 
data. SLD values were calculated by summing scattering length contributions over all atoms per 
molecule and dividing by the molecular volume. The volume of F127 per micelle was then calculated 
and divided by the molecular volume to give the aggregation number. The molecular volume of F127 
was previously determined by Bogomolova et al. (2013).35 
 
Synthesis of RITC labelled F127 
Rhodamine B isothiocyanate (RITC) was conjugated to F127 via the terminal hydroxyl groups.  
RITC (1 mg.mL-1) was added to 10 wt% solution of F127 in DMSO and stirred at room temperature in 
the dark for a minimum of 48 hours to enable conjugation. Preparations were then subsequently 
dialysed against 5L H2O with a MWCO of 3.5kDa and subjected to a minimum of three H2O changes 
in order to liberate any unbound dye. The F127-RITC conjugates were then freeze-dried to yield a solid 
preparation for further use.  Conjugation efficiency was verified using UV-Vis spectroscopy, and 
micelle formulations were prepared with low concentrations of RITC-F127 in order to eliminate 
influences of the dye molecules on micelle formation, uptake and cytotoxicity. 
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Synthesis of carboxylic acid terminated (anionic) F127 
A 10 wt% solution of F127 in H2O equating to 5g of F127 was prepared to which 175 mg sodium 
bromide, 75 mg 2,2,6,6,-tetramethyl-1-piperidinyloxyl (TEMPO) and 15 mL sodium hypochlorite 
solution containing 10-15 % available chlorine were added with the resulting mixture adjusted to pH11. 
The solution was left stirring overnight at room temperature with periodical pH adjustments upwards to 
pH11. Afterwards, the solution was quenched with 25 mL of ethanol and the reaction adjusted to pH1 
prior to solvent extraction with 3x100mL aliquots of chloroform. The organic fractions were 
subsequently washed with 3x100mL aliquots of H2O (pH1) prior to rotary evaporation at 42 °C and 
150 mbar for 60 minutes. Upon cooling to room temperature the resulting solid was dissolved in 
ethanol at 60 °C and then left overnight at -20 °C to recrystallise. The chilled ethanol solution was then 
decanted and the oxidised F127 product dried further using a rotary evaporator to remove residual 
ethanol. 
 
Synthesis of PEI labelled (cationic) F127 
Poly(ethylenimine) (PEI) with an average Mw of 1.3 kDa was conjugated to oxidised F127 mediated 
by EDC.36 In brief 100 μL of 50% (v/v) PEI in H2O was mixed with 2 mL of 10 wt% (10% oxidised) 
F127 in H2O to which 33 mg of EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) 
and 40 mg NHS (N-Hydroxysuccinimide) is added and adjusted to pH 4 for a minimum of 24 hours. 
Preparations were then subsequently dialysed against 5L H2O with a MWCO of 3.5kDa and subjected 
to a minimum of three H2O changes in order to liberate any unbound PEI. The F127-PEI conjugate was 
then freeze-dried to yield a solid preparation for further use. 
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Microscopy 
Widefield microscopy was performed using a Leica DMI6000 inverted epifluorescence microscope 
coupled with a Leica DFC365FX monochrome CCD camera in a temperature (37 °C) controlled 
environment equipped with a range of 5x to 100x dry/oil objectives. Confocal microscopy was 
performed using a Leica SP8 AOBS confocal laser scanning microscope attached to a Leica DM I6000 
inverted epifluorescence microscope with ‘Adaptive Focus Control’ in a temperature (37 °C) controlled 
environment with a range of 10x to 100x dry/oil objectives.  
 
Assessment of Pluronic F127 cytotoxicity on hMSCs 
Human mesenchymal stem cells (hMSCs) (passage 3) were cultured in a 96-well plate until confluent 
in hMSC medium (DMEM (low glucose), 10% (v/v) FBS, 2mM Glutamax, 100 units/mL Penicillin 
and 100 μg/mL Streptomycin). Each well was then replaced with 160 μL hMSC media plus 40 μL pre-
prepared F127 micelles (0 - 10 wt%) with 4 replicates and incubated at 37 °C / 5% CO2 for 18 hours 
yielding a final concentration of Pluronic F127 between 0 – 2 wt%. Cells were washed with 200 μL 
PBS prior to metabolic activity assessment by established Alamar Blue assays. 
 
In vitro drug sensitivity with hMSCs 
hMSCs (passage 2) were placed in 96-well plates in hMSC media until confluent. Cells were 
incubated with 160 μL hMSC media plus 40 μL pre-prepared F127/PTL micelles (0 wt% - 2.5 wt% 
F127) or 40 μL PTL co-solvent (2.5% methanol (v/v)) with a final PTL concentration varying from 0 
μM – 10 μM and 0.5 wt% F127 (n=4). Cells were then incubated at 37 °C / 5% CO2 for 24 hours and 
washed with 100 μL PBS prior to metabolic activity assessment by established Alamar Blue (24 hours) 
assays. 
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In vitro drug sensitivity with T-ALL cells 
Cryopreserved primary T-ALL cells were thawed and initial cell viability (> 60%) measured by flow 
cytometry using propidium iodide (PI)(Miltenyi Biotec Ltd, Bisley, UK). Cells were plated as 160 μL 
aliquots in triplicate in a round-bottom 96 well plate (4x104 live cells per well) in RPMI 1640 
supplemented with 25% (v/v) FBS, 2mM Glutamax, 100 units/mL Penicillin and 100 μg/mL 
Streptomycin prior to the addition of 40 μL of the corresponding F127 preparation and incubated at 37 
°C / 5% CO2 / 5% O2 for 24 hours. Cells were then centrifuged at 500g for 5 minutes at room 
temperature and the supernatant discarded. Cells were resuspended in 100 μL of 2.5 %(v/v) Annexin-V 
solution (Miltenyi Biotec Ltd) and incubated in the dark at room temperature for 10 minutes. 
Afterwards 100 μL of Annexin-V buffer was added prior to a second wash step. The supernatant was 
discarded and cells resuspended in 100 μL of Annexin-V buffer and cooled to 4°C prior to analysis. 
Analysis was performed on a MACSQuant® Analyser 10 flow cytometry (Miltenyi Biotec Ltd) with 
the pre-addition and mixing of PI to allow differentiation between necrosis and apoptosis. The resulting 
data was analysed using FlowJo single cell analysis software (FlowJo LLC, OR, USA) gated for the 
selection of lymphocytes and further gated to into quadrants comprising live, early apoptotic, late 
apoptotic and dead cells (Supplementary Figure. 15). Viabilities are expressed as a percentage of 
untreated controls.  
  
LogP and Volume Calculations and Statistics 
Theoretical calculations to determine LogP and (van der Waals) surface area values of F127, PTL, 
and DPH were derived using MarvinSketch 16.1.25.0 (release date 2016) accessible at 
http://www.chemaxon.com. Data interpretation, numerical and statistical analysis were performed 
using Microsoft® Excel® for Mac 2011 (Microsoft Corporation, WA, USA), Origin 9.0 (Originlab 
 13 
Corporation, MA, USA) and Prism 7 for Mac OS X (Graph Pad Inc, CA, USA). IC50 values were 
defined using a sigmoidal dose response algorithm.  
 
Mass spectrometry (MALDI-TOF). 
Matrix assisted laser desorption ionisation time of flight (MALDI-TOF) mass spectrometry was 
performed on a UltrafleXtreme mass spectrometer (Bruker (UK) Ltd, Coventry, UK) using a matrix of 
containing a saturated solution of α-Cyano-4-hydroxycinnamic acid in acetonitrile with 0.1% 
trifluoroacetic acid in an 1:1 ratio of sample in H2O mixed and spotted onto a 384 well plate with a 
ground steel surface prior to ionisation and detection (100% laser power / +ve ion mode. Analysis was 
performed using the open source software mMass (v. 5.5)37 accessible at http://www.mmass.org/. 
 
Fourier transform infrared spectroscopy (FTIR). 
FTIR spectroscopy was performed on a Spectrum One Fourier Transform Infra‑ Red (FTIR) 
spectrometer equipped with a universal attenuated total reflectance (ATR) sampling accessory (Perkin 
Elmer Inc, MA, USA). Small quantities of solid Pluronic and the oxidised and PEI analogues were 
separately placed over the quartz window and the sample tightened to ensure accurate measurement. A 
total of 8 replicates were performed and the averages were reported. The appearance of a carbonyl 
stretching vibration at 1740 cm-1 was indicative of successful oxidation and presence of a (anionic) 
carboxylic acid functional group. The appearance of an amine bond stretching vibration at 3410 cm-1 
was indicative of successful coupling and the presence of (cationic) amine functional groups derived 
from PEI. For chloroform detection small quantities of the appropriate F127 solution/emulsion was 
placed over the quartz window and the sample tightened to ensure accurate measurement. A total of 20 
replicates were performed and the averages were reported. The presence of chloroform could be 
monitored by the appearance of a carbon-chlorine stretching vibration at approximately 750 cm-1. 
  
 14 
RESULTS AND DISCUSSION 
Properties of F127 micelles. 
Pluronic molecules undergo a reversible monomer/micelle transition that is dependent upon both 
temperature (CMC) and concentration (CMT) and it was essential to understand this behaviour for 
effective vector design (Table 1).26 The Pluronic molecule (Figure 1B) F127 (Poloxamer 407) was 
selected as it is widely available and FDA approved as a pharmaceutical ingredient and foodstuff.33,38 
MALDI-TOF mass spectrometry from the F127 gave a mass of 13.5 ± 0.8 kDa (FWHM), which was 
close to the theoretical value of 12.6 kDa (Supplementary Figure 1). Discrepancies between MALDI-
TOF mass spectrometry and the theoretical value can be explained in part due to shifts in the polymer 
mass distribution often associated with this technique.39 F127 and acid- or poly(ethylenimine)-modified 
analogues (see Materials and Methods for the synthesis of carboxylic acid terminated and PEI labelled 
F127) were used to produce PTL loaded micelles (Figure 1C) with neutral, anionic or cationic 
peripheral surface charges respectively (Figure 1D).  
Table 1: Properties of F127 with respect to size, phase and aggregation number. 
Property F127 
Monomeric hydrodynamic diameter (DLS) 3.4 ± 0.2 nm (5 wt% / 4 °C) (PDI; 0.254 at 10°C) 
Micelle hydrodynamic diameter (DLS)  20.2 ± 0.3 nm (5 wt% / 37 °C) (PDI; 0.048 at 37 °C) 
Micelle diameter (SAXS) 19.2 ± 2.2 nm (2 wt% / 31 °C) 
20.0 ± 2.0 nm (2 wt% / 37 °C) 
20.7 ± 1.9 nm (2 wt% / 49 °C) 
CMT (DPH) 25  ± 1°C  (2 wt%) 
CMT (DLS) 25  ± 1°C (1 wt%) 
CMC (DPH) 1.5  ± 0.25 wt% (25 °C) 
Aggregation No. (SLS) 
 
40 ± 2 (50 °C) 
 Aggregation No. (SAXS) 46 ± 2 (37 °C) Mass (MALDI-TOF) 13.5 ± 0.8 kDa 
 
* DLS - dynamic light scattering 
† SAXS - small angle x-ray scattering  
†† DPH - 1,6-diphenyl-1,3,5-hexatriene (DPH) assay. 
** SLS – static light scattering 
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Dynamic light scattering (DLS) measurements of 5 wt% aqueous solutions of F127 at 4 and 37 °C 
gave hydrodynamic diameters 3.4 ± 0.2 nm and 20.2 ± 0.3 nm for the monomeric and micelle phases of 
unmodified F127 respectively (Figure 2A). Monitoring changes in hydrodynamic diameter with 
respect to temperature allowed the determination of the CMT (25 ± 1°C) (Figure 2B). This was 
complemented by an absorbance/fluorescence based micellization assay utilising the hydrophobic dye 
1,6-diphenyl-1,3,5-hexatriene (DPH), which gave a CMT value of 25 ± 1°C. Here, upon micelle 
formation and the subsequent sequestration of DPH into the hydrophobic core, a considerable change 
in the fluorescence depolarization of DPH causes a substantial increase in absorbance and fluorescence 
enabling the onset of micelle formation to be identified with respect to both the CMT and CMC 
(Figure 2B & Figure 2C).40 An aggregation number of 40 ± 2 was evaluated by SLS using previously 
reported refractive index increment values for F127 at 25 °C and 50 °C with a comparable value of 46 
± 2 (37 °C ) determined by SAXS (Supplementary Figure 2 & Supplementary Table 1).41 This was 
crucial in estimating the micelle number density, number of PTL molecules per micelle and average 
peripheral surface charge. The aggregation number is known to increase with temperature although 
with no observed increase in hydrodynamic diameter via DLS, which has been shown in part to be due 
to the H2O hydration of the PEO blocks.42,43 Accordingly, temperature-dependent small angle x-ray 
scattering (SAXS) experiments were used to probe changes in micelle diameter with respect to 
temperature, which showed a 1.5 nm increase in the particle radius as the temperature was increased 
from 31 to 49 °C (Supplementary Figure 3 & Table 1).  
 
Incorporation of anionic and cationic peripheral surface charge. 
The inclusion of peripheral surface charges can begin to introduce elements of specificity and 
targeting as well as expanding chemical functionality for further modification. In order to initiate a 
peripheral anionic surface charge, the terminal hydroxyl groups of F127 were quantitatively oxidised to 
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yield carboxylic acid functional groups. Effective oxidation was confirmed by Fourier Transform 
Infrared (FTIR) spectroscopy with the appearance of a peak at 1740 cm-1, indicative of a carbonyl 
(C=O) stretch (Supplementary Figure 4).  
 
 
 
 
 
 
 
 
 
 
Figure 2: Characterisation of F127 Micelles A. Dynamic light scattering of F127 below and above the 
CMC and CMT highlighting the hydrodynamic radius of the monomeric and micelle species. B. CMT 
evaluation of F127 by DLS (1 wt%) and the DPH (2 wt%) assay. C. CMC evaluation of F127 by the 
DPH assay at 25 °C. D. DLS of 1 wt% F127 micelles with a range of oxidised substituents (0-10%) in 
PBS at 37 °C. E. DLS of 1 wt% F127 micelles conjugated with PEI in PBS at 37 °C. F.  Zeta potential 
of F127 (neutral), Oxidised F127 (anionic) and PEI-F127 (cationic) at pH 7.1. 
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Preparations consisting of 100% oxidised F127 significantly reduced the cloud point transition 
temperature from in excess of 65 °C for unmodified F127 to 25 °C for a 100% oxidised preparation at 1 
wt%, rendering the formulation unusable for vector design. However, creating a blend consisting of 
50% oxidised F127 and 50% F127 did alleviate this effect (Supplementary Figure 5). As the oxidised 
content was increased from 0 to 10%, a reduction in DPH fluorescence was also observed 
(Supplementary Figure 6) without a significant change (p-value >0.05) in the hydrodynamic diameter 
of the corresponding micelles (Figure 2D & Table 2). 
A reduction in DPH fluorescence was consistent with an increase in the dielectric constant of the 
micelles arising from the charged headgroups. Therefore, micelles with an oxidised content equating to 
10% (average of 4 oxidised monomers per micelle) were taken forward for subsequent in vitro 
experiments. For cationic particle synthesis, poly(ethylenimine) (PEI) (≈ 1.3 kDa) was coupled to the 
oxidised F127 adduct and efficient coupling was verified by the presence (3410 cm-1) of N-H stretching 
vibrations in the resulting FTIR spectra (Supplementary Figure 4). DLS experiments performed on 
the PEI conjugated cationic micelles (10% PEI content) showed a 2 nm increase (p-value <0.0001) in 
hydrodynamic diameter when compared with the pristine particles (Figure 2E, Table 2), although no 
increase in radius was observed by SAXS, which was consistent with a diffuse low contrast PEI corona 
with aggregation number (SAXS) values comparable to the pristine particles (Table2, Supplementary 
Table 2 and Supplementary Table 3) 
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Table 2: Properties of oxidised F127 and PEI conjugated F127 with respect to micelle size and 
aggregation number at various levels of oxidised or PEI content. Values represent the mean ± standard 
error. 
Property Oxidised F127 PEI-F127 
Micelle hydrodynamic diameter (DLS) 20.2 ± 0.3 nm (0% /5 wt%) 
17.2 ± 0.3 nm (0% /1 wt%) 
17.9 ± 0.3 nm (1% /1 wt%) 
17.7 ± 0.3 nm (5% /1 wt%) 
17.7 ± 0.3 nm (10% /1 wt%) 
22.9 ± 0.3 nm (10% /5 wt%) 
Micelle diameter (SAXS) 20.1 ± 0.1 nm (10% /2 wt%) 20.0 ± 0.1 nm (10% /2 wt%) 
Aggregation No. (SAXS) 45 ± 2 (10% /2 wt%; 37 °C) 43 ± 2 (10% /2 wt%; 37 °C) 
 
* DLS - dynamic light scattering 
† SAXS - small angle x-ray scattering  
 
PEI and nanoparticles displaying PEI have been shown to have a high affinity for the anionic cell 
membrane surface and have been used as transfection agents for DNA delivery.44,45 However, high MW 
PEI cations can promote the aggregation/cross-linking of cells in suspension as well as being 
cytotoxic.46-48 Therefore, it was postulated that low MW PEI displaying F127 micelles may have a 
greater affinity for the cell membrane and further enhance solvent-free PTL uptake. To estimate the 
surface charge of each of the systems, zeta potentiometry was undertaken. Here, 2 mg.mL-1 micelle 
preparations at pH 7.1 (Figure 2F) gave zeta potentials of -16.5 ± 0.9 mV, +10.8 ±1.6 mV, and -3.2 ± 
2.1 mV for the anionic, cationic and neutral particle systems, respectively.  
 
Formulation of PTL loaded F127 micelles 
Due to the insolubility of PTL in the aqueous phase and the toxicity of organic solvents the formation 
of PTL loaded F127 micelles (Figure 1C) was performed using a modified strategy derived from 
Collins et al. and was systematically applied across all three charged systems.30 A notable difference in 
the synthesis was the implementation of a rotary evaporator step to eliminate chloroform as opposed to 
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microwaves, as rotary evaporation offers a greater degree of control and limits water loss. Here PTL 
(≈20 mg.mL-1) dissolved in chloroform (5% (v/v)) was used as the droplet phase in an oil-in-water 
emulsion, which was stabilised by the presence of the F127 (Supplementary Figure 7 & 
Supplementary Figure 8). The high log P value of PTL (3.07) ensured retention in the (hydrophobic) 
oil (CHCl3) droplets. Complete removal of chloroform resulted in the collapse of the F127 stabilised 
emulsion droplets resulting in the formation of the PTL-loaded micellar structures. The removal of 
chloroform was confirmed by FTIR equipped with an ATR accessory and the elimination of a carbon-
chloroform stretching vibration at 750 cm-1 (Supplementary Figure 9). The preparative mixtures (10 
wt% F127, 2.42 mM PTL) yielded micelles with an average of 22 PTL molecules per particle and no 
large aggregates were detected, indicating complete PTL incorporation. The ability to systematically 
vary the concentration of PTL in F127 micelle systems was dependent upon a number of factors: the 
solubility of PTL in chloroform; the chloroform/aqueous F127 ratio for emulsion stabilisation; which in 
turn was dependent upon the concentration of (≈10 %(v/v)) CHCl3 in an aqueous 10 wt% F127 solution 
(Supplementary Figure 10)); and finally the maximum stable loading of PTL per micelle/F127 
molecule. Estimation of the van der Waals volume of PTL indicated that the addition of PTL would 
only constitute an approximate 1% increase in the total micelle volume, which was consistent with 
DLS measurements that showed no appreciable changes in the particle hydrodynamic diameter. SAXS 
measurements also showed no significant increase in size for the pristine particles after the addition of 
PTL, but an increase in particle radius was observed for both the anionic and cationic micellar systems 
(Supplementary Figure 11), indicating a change in the packing density of the charged monomers 
arising from repulsive electrostatic headgroup interactions. Significantly, attempts to directly dissolve 
PTL into a concentrated micellar solution of F127 (>10 wt%) were unsuccessful, demonstrating the 
utility of the emulsion transfer methodology. Over the concentration range investigated, no PTL 
precipitate or significant change in size (p-value =0.9996) were detected (DLS) even after prolonged 
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exposure at 4 °C (below the CMT), which indicated that PTL (248 Da) could remain co-solvated by 
monomeric F127 (12.6 kDa) due to the low PTL:F127 (0.5:1) stoichiometry. Moreover, heating the 
sample back to 42 °C resulted in micelle formation with no significant (p-value = 0.9979) differences 
in the particle hydrodynamic diameters (Supplementary Figure 12). Complementary temperature-
dependent SAXS experiments supported the DLS observations, showing no apparent change in the 
micelle diameter or PTL aggregate formation after a thermal cycle between 37 °C and 4 °C 
(Supplementary Figure 13). Significantly, increasing the PTL particle loading by an order of 
magnitude did result in visible PTL precipitate after storage (48 hour) at 4 °C. The ability to thermally 
cycle the system without the loss of sequestered PTL was significant, as retaining a consistent 
temperature above the CMT during an entire supply chain process of a therapeutic would be 
prohibitive. Moreover, low temperatures (e.g., 4 or -20 °C) are preferable to maintain sterility and 
prolong the shelf life of the active (drug) component. 
 
Cell uptake and efficacy  
Assessing the uptake and internalization and the resulting efficacy of PTL is critical for investigating 
the use of PTL loaded F127 micelles as a potential therapeutic. Bone marrow derived human 
mesenchymal stem cells (hMSCs) were assayed initially as they are well characterised and occupy a 
similar niche to lymphoblasts associated with ALL, though notable differences with respect to 
nanoparticle uptake and interaction may still exist.49,50 Interactions between PTL-free rhodamine 
labelled F127 (biocompatible) micelles and hMSCs were studied using widefield fluorescence 
microscopy, which showed strong cell association after 15 minutes (Supplementary Figure 14). To 
probe the internalisation of F127, confocal fluorescence microscopy was utilised which showed F127 
(red) in the cytoplasm but not in the nucleus (blue) (Figure 3A and Figure 3B), which was consistent 
with previously reported findings that utilised Nile Red as fluorescent hydrophobic probe in core cross-
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linked poly(pentaerythritol tetraacrylate) stabilised F127 micelles.51 It was not clear whether or not 
micelles or monomeric species persisted in the intracellular or membrane bilayer environment. Indeed, 
if PTL molecules were immobilised at the cytoplasmic membrane surface, it is possible that the drug 
would be internalised and progressed along its standardised chemotherapeutic pathway (e.g. NF-κB 
inhibition, p53 activation etc.), inducing apoptosis20,22,24,52 by a mechanism similar to co-solvent 
administered PTL. However the internalisation of micelles or monomers (with associated PTL) and 
subsequent liberation of PTL cannot be ruled out.  
 
To ensure that F127 micelles devoid of PTL but subjected to the same synthetic process (i.e. CHCl3 
addition and removal) did not incite cytotoxicity, hMSCs were incubated over a 18-hour period with 
subsequent cell metabolic activity (alamar blue)53 measured. Even at the highest concentration tested (2 
wt%) (Figure 3C), no cytotoxicity was observed, which is consistent with previous reports.51,54 To 
investigate the intracellular delivery of PTL (72 µM), an initial qualitative evaluation by widefield 
microscopy of each F127 (1.5 wt%) charge type and co-solvent formulation was undertaken. The rapid 
(10 minutes) onset of toxicity indicated by changes in morphology and rounding (Figure 3D, Figure 
3E & Supplementary Figure 15) showed qualitatively that PTL loaded F127 micelles still possessed 
an efficacious effect albeit at a concentration exceeding that of previous reported IC50 values attained 
with other cell types.21-25  
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Figure 3: A. Confocal micrograph highlighting the retention of (PTL free) 2 wt% F127-RITC (red) and 
Hoechst 33342 (blue) after a 30 minute incubation with hMSCs cells. B. 3D projection of hMSCs 
highlighting distribution of F127-RITC (red) compared to Hoechst 33342 (blue). C. Relative cell 
metabolic activity (Alamar Blue) of hMSCs after an 18-hour exposure with various concentrations of 
unmodified Pluronic F127. Measurements are compared to an untreated control with the mean + 
standard deviation of at least 3 replicates reported. D. Micrograph of live hMSCs prior to 
administration of 72 μM PTL in 1.5 wt% F127 micelles. E. Micrograph of hMSCs treated with 72 μM 
PTL in 1.5 wt% F127 micelles after 45 minutes displaying significant altered morphology/rounding. 
Leading on from this, quantitative dose response curves of each F127 micelle class (Figure 1D) were 
generated against hMSCs after an 18 hour incubation period (Figure 4) (allowing the onset of 
apoptosis), which revealed a reduction in cell metabolic activity (alamar blue) due to cell death, 
yielding IC50 values of 2.3 ± 0.2 µM, 2.8 ± 0.2 µM and 3.0 ± 0.2 µM for the cationic, neutral and 
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anionic preparations respectively. Differences between Pluronic and co-solvent (IC50 = 1.8 ± 0.1 μM) 
preparations were apparent, though evidently the use of F127 can substitute the need for co-solvent 
(methanol) administration without a substantial loss of efficacy.  
 
  
 
 
 
 
 
Figure 4: Dose response curves of various PTL formulations against hMSCs (passage 3) measuring 
cell metabolic activity (alamar blue) relative to untreated controls. A. 0.5 wt% F127/PTL formulation. 
B. 0.5 wt% 10% Oxidised F127/PTL formulation. C. 0.5 wt% PEI-F127/PTL formulation. D. Standard 
(2.5% v/v) methanol/PTL co-solvent formulation. Values reported represent the mean of at least three 
replicates and error bars ± standard deviation. IC50 values are derived from sigmoidal dose-response 
curves with errors representing standard error. 
Differences between each of the charged formulations may be rationalised by consideration of the 
cell membrane surface charge. Specifically, the presence of predominantly anionic glycoproteins, 
oligosaccharides and other elements of the glycocalyx generate regions of anionic surface charge, 
which has been shown to detrimentally influence the interaction and uptake of nucleic acids and other 
anionic constructs55, which can be overcome by the introduction of cationic residues.56-58 Therefore, it is 
probable that the presence of cationic PEI promoted greater retention at the cell membrane resulting in 
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an increased probability of endocytosis when compared with the anionic or neutral particles. Indeed 
charge-mediated repulsion may explain the reduction in efficacy for the anionic system. 
In light of the encouraging results from the hMSC assays, primary T-ALL cells were assessed as a 
more clinically relevant and direct measure of these F127 micelle preparations, especially as 
differences between the uptake of anionic and cationic nanoparticles between different cell types has 
been previously reported.27-29,49,59 Previous endpoint (alamar blue) assays focused on the resulting cell 
metabolic activities of hMSCs, however, these assays do not discriminate between necrosis and 
apoptosis.  Accordingly, an annexin-V/PI based flow cytometry assay60 was implemented to 
differentiate between apoptotic and non viable (PI+) populations and attribute apoptotic cell death 
caused by PTL (Supplementary Figure 16). Importantly no significant cytotoxicity was detected with 
a 2 wt% F127 (PTL free) solution with cell viability remaining close to untreated controls (96.4% ± 
9.8%). Each F127 preparation induced apoptosis of T-ALL cells, with dose response curves reported 
(Figure 5) comparable to values in co-solvent administrated preparations, again highlighting the ability 
for co-solvent elimination. While, the variations arising from differences in charge were less clear, 
Patient A showed a reduction in efficacy in the anionic and cationic formulations, this was not apparent 
with Patient B and Patient C, with distinctions in patient response typical of the disease.19 However, 
F127-PTL was most effective across the patient samples tested achieving higher levels of T-ALL cell 
killing using lower doses of drug (<2.4µM). 
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Figure 5:  Dose response curves of all PTL formulations against patient T-ALL cells measuring 
apoptosis (Annexin V) and necrosis (propidium iodide) relative to untreated controls. A. Patient A. B. 
Patient B. C. Patient C. Values reported represent the mean of at least three replicates and error bars ± 
standard deviation. IC50 values are derived from sigmoidal dose-response curves with errors expressed 
as the standard error. 
 In these cases, the dose response associated between hMSCs and T-ALL cells did not differ 
dramatically such that no obvious therapeutic window could be derived, which further emphasises the 
importance of targeting/homing to limit systemic exposure. However, the utility and biocompatibility 
of using solvent-free formulations is highly attractive and another consideration is that in vivo 
dosimetry profiles of free (i.e. cytotoxic co-solvent) PTL tend to require multiple doses due to the 
relatively short half-life (<90 minutes in human liver microsomes), which could lead to an 
accumulation of the co-solvent.61 Pluronic micelles have been reported to enhance the pharmacokinetic 
profile of the chemotherapeutic paclitaxel and therefore the use of F127 micelles may allow for a more 
infrequent and controlled dosimetry in vivo.62 The effect of charge on micelles administered in vivo 
may also be more pronounced with respect to charge mediated attraction/repulsion, as the site of 
administration is often different (i.e. intravenous, intraperitoneal, oral etc.) to the desired treatment 
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locale. The effect of charge in a more biorelevant system may therefore be more pronounced with 
regards to distribution and persistence as seen with other polymer based micelle systems.63  
  
Recent work has highlighted how in biological fluids both in vitro and in vivo a (plasma) protein 
corona often forms around nanoparticles that can influence their fate within living systems.64,65 
However, the extent of how this effect may impact pathophysiology is dependent on many factors, 
including the inherent nanoparticle composition and surface.66,67 Surface modifications, such as the 
PEGylation of nanoparticles or drugs have been shown to limit (but not eliminate) protein adsorption. 
Indeed, protein adsorption to PEGylated surfaces appears to be necessary in order to prolong 
circulatory half-life and reduce non-specific cellular uptake, i.e., the "stealth effect” could be a 
prerequisite for specific targeting strategies.68-70 Similar mechanisms have been reported with Pluronic-
based coatings in extending circulatory times71-73 as well as with a range of amphiphilic block co-
polymer micelles akin to those used here including the use of diblock poly(styrene-alt-maleic 
anhydride) -b- poly(styrene) micelles for solvent mediated PTL sequestration and delivery against the 
AML cell line MV4-11.74,75 Furthermore, the enhanced permeability and retention (EPR) effect, which 
is the preferential uptake and localisation into tumour or infarcted tissues due to the surrounding 
abnormal vasculature, has been shown to benefit many nanoparticle/drug preparations, which further 
emphasises a potential advantage of F127 based systems in vivo over a co-solvent based 
formulation.76,77 Nevertheless, different polymer based coatings can induce different effects. For 
example, PEGylated lipid nanocapsules have been shown to not impact on human monocytes, whereas 
Pluronic (F68) coated lipid nanocapsules have been shown to heighten activation of human monocytes 
but were inert against T-cells, emphasising how polymeric interfaces can modulate cell interactions as 
well as reducing non-specific binding.78 
 
 27 
CONCLUSIONS 
Solvent-free PTL containing F127 micelles with various peripheral surface charges were synthesised 
and characterised with respect to their physicochemical behaviour, highlighting the stable incorporation 
and retention of PTL with thermal reversibility between monomeric and micelle phases. Furthermore, 
the efficacy of each formulation as a chemotherapeutic delivery agent in the treatment of ALL in vitro 
was demonstrated. Small differences arising from charge-mediated membrane interactions caused 
changes with their efficacy in vitro, with anionic formulations having reduced relative efficacy. 
However, efficacy was comparable to that of a co-solvent based formulation, highlighting how a 
solvent-free formulation could be developed as a substitute, thereby removing the requirement for 
cytotoxic co-solvents in treatments. Moreover, the synthesis of the particles displaying surface bound 
synthetically accessible groups provides the possibility for the incorporation of additional functionality, 
for example, increases in cell specificity for the treatment of ALL could be achieved via antibody 
conjugation. In conclusion, the inherent tunability, enhanced retention and improved pharmacokinetics 
of polymer-based systems in general in vivo62,63,71,72 along with the introduction of peripheral 
functional groups may enable the future production and delivery of micelle species with improved 
targeting to the bone marrow niche and maximise the chemotherapeutic potential of PTL. 
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